Dianolyn Capsules Recalled

First public notice issued by FDA of 'completed recall'...

Alhambra, CA (SafetyAlerts) - The Food and Drug Administration (FDA) today reported that Diabetic Capital (U.S.) LLC is conducting a recall of Dianolyn Capsules because the product fails to declare prescription drug ingredient glyburide.

PRODUCT
Dianolyn(tm) Capsules, OTC oral dietary supplement, in bottles of 30.

Recall #D-439-0.  Class I

CODE
Lot #0914 EXP 10/02.

MANUFACTURER
Phyytos Nutri-Pharma, Corona, California. (contract manufacturer).

RECALLED BY
Diabetic Capital (U.S.) LLC, Alhambra, California (responsible firm), by telephone on March 16, 2000, by press release on March 22, 2000, and by letter on March 24, 2000. Firm-initiated recall complete.  This is the first public notice issued by the FDA.

DISTRIBUTION
California, Florida, Georgia, Kansas, Louisiana, Maryland, Missouri, Oregon, Pennsylvania, Texas, Virginia and the District of Columbia.

QUANTITY
10,788 boxes were distributed.

Questions concerning this recall may be directed to the FDA at 1-888-INFO-FDA.

Notice of this product warning was sent via email to SafeMail subscribers August 1, 2000.

Safety Alerts compiles comprehensive safety recall information for the United States. SafeMail is a free email service to warn consumers of faulty products and contaminated foods. For complete information regarding current recalls, past recalls and timely product warning notification visit: www.safetyalerts.com.

###